427 related articles for article (PubMed ID: 27777238)
21. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
22. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
Chang Y; Min J; Jarusiewicz JA; Actis M; Yu-Chen Bradford S; Mayasundari A; Yang L; Chepyala D; Alcock LJ; Roberts KG; Nithianantham S; Maxwell D; Rowland L; Larsen R; Seth A; Goto H; Imamura T; Akahane K; Hansen BS; Pruett-Miller SM; Paietta EM; Litzow MR; Qu C; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
Blood; 2021 Dec; 138(23):2313-2326. PubMed ID: 34110416
[TBL] [Abstract][Full Text] [Related]
23. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
Meyer LK; Delgado-Martin C; Maude SL; Shannon KM; Teachey DT; Hermiston ML
PLoS One; 2019; 14(7):e0220026. PubMed ID: 31318944
[TBL] [Abstract][Full Text] [Related]
24. Levels of p27 sensitize to dual PI3K/mTOR inhibition.
Lee M; Theodoropoulou M; Graw J; Roncaroli F; Zatelli MC; Pellegata NS
Mol Cancer Ther; 2011 Aug; 10(8):1450-9. PubMed ID: 21646547
[TBL] [Abstract][Full Text] [Related]
25. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
26. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.
Janes MR; Vu C; Mallya S; Shieh MP; Limon JJ; Li LS; Jessen KA; Martin MB; Ren P; Lilly MB; Sender LS; Liu Y; Rommel C; Fruman DA
Leukemia; 2013 Mar; 27(3):586-94. PubMed ID: 23090679
[TBL] [Abstract][Full Text] [Related]
28. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
30. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
31. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
32. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.
Beale G; Haagensen EJ; Thomas HD; Wang LZ; Revill CH; Payne SL; Golding BT; Hardcastle IR; Newell DR; Griffin RJ; Cano C
Br J Cancer; 2016 Sep; 115(6):682-90. PubMed ID: 27529512
[TBL] [Abstract][Full Text] [Related]
33. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
34. Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL.
Guo Y; Li Y; Xiang B; Huang XO; Ma HB; Wang FF; Gong YP
Biochem J; 2017 Dec; 474(24):4153-4170. PubMed ID: 29046392
[TBL] [Abstract][Full Text] [Related]
35. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH
Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059
[TBL] [Abstract][Full Text] [Related]
36. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.
Hart S; Novotny-Diermayr V; Goh KC; Williams M; Tan YC; Ong LC; Cheong A; Ng BK; Amalini C; Madan B; Nagaraj H; Jayaraman R; Pasha KM; Ethirajulu K; Chng WJ; Mustafa N; Goh BC; Benes C; McDermott U; Garnett M; Dymock B; Wood JM
Mol Cancer Ther; 2013 Feb; 12(2):151-61. PubMed ID: 23270925
[TBL] [Abstract][Full Text] [Related]
37. Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.
May CD; Landers SM; Bolshakov S; Ma X; Ingram DR; Kivlin CM; Watson KL; Sannaa GAA; Bhalla AD; Wang WL; Lazar AJ; Torres KE
Cancer Biol Ther; 2017 Oct; 18(10):816-826. PubMed ID: 29099264
[TBL] [Abstract][Full Text] [Related]
38. Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.
Evangelisti C; Chiarini F; Cappellini A; Paganelli F; Fini M; Santi S; Martelli AM; Neri LM; Evangelisti C
J Cell Physiol; 2020 Jun; 235(6):5413-5428. PubMed ID: 31904116
[TBL] [Abstract][Full Text] [Related]
39. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
Yu P; Laird AD; Du X; Wu J; Won KA; Yamaguchi K; Hsu PP; Qian F; Jaeger CT; Zhang W; Buhr CA; Shen P; Abulafia W; Chen J; Young J; Plonowski A; Yakes FM; Chu F; Lee M; Bentzien F; Lam ST; Dale S; Matthews DJ; Lamb P; Foster P
Mol Cancer Ther; 2014 May; 13(5):1078-91. PubMed ID: 24634413
[TBL] [Abstract][Full Text] [Related]
40. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
Yang X; He G; Gong Y; Zheng B; Shi F; Shi R; Yang X
Eur J Haematol; 2014 Feb; 92(2):111-20. PubMed ID: 24112092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
